Venus Remedies Limited

NSE VENUSREM.NS

Venus Remedies Limited Capital Expenditure for the year ending March 31, 2024: USD -1.62 M

Venus Remedies Limited Capital Expenditure is USD -1.62 M for the year ending March 31, 2024, a -70.38% change year over year. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).

Venus Remedies Limited Capital Expenditure for the year ending March 31, 2023 was USD -951.22 K, a 47.31% change year over year.
Venus Remedies Limited Capital Expenditure for the year ending March 31, 2022 was USD -1.81 M, a -71.06% change year over year.
Venus Remedies Limited Capital Expenditure for the year ending March 31, 2021 was USD -1.06 M, a -2.21% change year over year.
Venus Remedies Limited Capital Expenditure for the year ending March 31, 2020 was USD -1.03 M, a 27.70% change year over year.

Key data

Date	Capital Expenditure	Free Cash Flow	Depreciation And Amortization	Deferred Income Tax

NSE: VENUSREM.NS

Venus Remedies Limited

CEO	Mr. Ashutosh Jain B.A., LL.B
IPO Date	Dec. 20, 2006
Location	India
Headquarters	Plot 51-52, Industrial Area
Employees	1,187
Sector	Health Care
Industries Pharmaceuticals Drugstores & Retail Pharmacies

Description

Venus Remedies Limited develops and markets pharmaceutical products in India and internationally. The company offers its products in various therapeutic areas, such as analgesic, analgesic and antipyretic, anti-diabetic, antibiotic, anticoagulant, cardiac, disinfectant and antiseptic, gastro therapy, hand sanitizers, hormones, iron supplements, neurology, oncology, pain management, respiratory, skin and wound care, stress reliever, urology, and vitamins/minerals/nutrients, as well as antimicrobial resistance products. It also provides disinfectants; and a portfolio of herbal products. Venus Remedies Limited was incorporated in 1989 and is headquartered in Panchkula, India.

Key trends

Past 5 years